Last updated on January 2019

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma


Brief description of study

To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.

Clinical Study Identifier: NCT02760498

Find a site near you

Start Over

City of Hope Hospital

Duarte, CA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

St. Louis University

Saint Louis, MO United States
  Connect »

New York University

New York, NY United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »

Mayo Clinic

Phoenix, AZ United States
  Connect »

Stanford University

Redwood City, CA United States
  Connect »

Adelaide Cancer Centre

Kurralta Park, Australia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.